» Articles » PMID: 38608215

Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Abstract

Purpose: Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS).

Patients And Methods: This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort).

Results: In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis.

Conclusion: The new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.

Citing Articles

External validation and calibration of the HoLISTIC Consortium's advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the Brazilian Hodgkin lymphoma registry.

Buccheri V, Moreira F, Biasoli I, Castro N, Villarim C, Traina F Br J Haematol. 2024; 206(1):144-151.

PMID: 39419492 PMC: 11747895. DOI: 10.1111/bjh.19824.


Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management.

Caserta S, Cancemi G, Loreta S, Allegra A, Stagno F Diagnostics (Basel). 2024; 14(13).

PMID: 39001280 PMC: 11241324. DOI: 10.3390/diagnostics14131390.

References
1.
Wey A, Connett J, Rudser K . Combining parametric, semi-parametric, and non-parametric survival models with stacked survival models. Biostatistics. 2015; 16(3):537-49. PMC: 5963472. DOI: 10.1093/biostatistics/kxv001. View

2.
Uno H, Cai T, Pencina M, DAgostino R, Wei L . On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011; 30(10):1105-17. PMC: 3079915. DOI: 10.1002/sim.4154. View

3.
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D . PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017; 390(10114):2790-2802. DOI: 10.1016/S0140-6736(17)32134-7. View

4.
Steyerberg E, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014; 35(29):1925-31. PMC: 4155437. DOI: 10.1093/eurheartj/ehu207. View

5.
Diefenbach C, Li H, Hong F, Gordon L, Fisher R, Bartlett N . Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015; 171(4):530-8. PMC: 4881845. DOI: 10.1111/bjh.13634. View